These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP). Thomalla G; Fiebach JB; Østergaard L; Pedraza S; Thijs V; Nighoghossian N; Roy P; Muir KW; Ebinger M; Cheng B; Galinovic I; Cho TH; Puig J; Boutitie F; Simonsen CZ; Endres M; Fiehler J; Gerloff C; Int J Stroke; 2014 Aug; 9(6):829-36. PubMed ID: 23490032 [TBL] [Abstract][Full Text] [Related]
10. Time to Wake-Up: Extending the Window for Management of Unknown-Onset Strokes. Fawaz AM; Wu S; Viswanathan D; Kaur K; Nuoman R; Nuoaman H; Adnan YA; Gandhi CD; Kurian C; Sahni R Cardiol Rev; 2021; 29(1):26-32. PubMed ID: 32769626 [TBL] [Abstract][Full Text] [Related]
11. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384 [TBL] [Abstract][Full Text] [Related]
12. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Thomalla G; Boutitie F; Ma H; Koga M; Ringleb P; Schwamm LH; Wu O; Bendszus M; Bladin CF; Campbell BCV; Cheng B; Churilov L; Ebinger M; Endres M; Fiebach JB; Fukuda-Doi M; Inoue M; Kleinig TJ; Latour LL; Lemmens R; Levi CR; Leys D; Miwa K; Molina CA; Muir KW; Nighoghossian N; Parsons MW; Pedraza S; Schellinger PD; Schwab S; Simonsen CZ; Song SS; Thijs V; Toni D; Hsu CY; Wahlgren N; Yamamoto H; Yassi N; Yoshimura S; Warach S; Hacke W; Toyoda K; Donnan GA; Davis SM; Gerloff C; Lancet; 2020 Nov; 396(10262):1574-1584. PubMed ID: 33176180 [TBL] [Abstract][Full Text] [Related]
13. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study. García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450 [TBL] [Abstract][Full Text] [Related]
14. In imaging-selected ischemic stroke with unknown onset, alteplase increases favorable outcomes and death at 90 d. Hill MD Ann Intern Med; 2021 Apr; 174(4):JC42. PubMed ID: 33819060 [TBL] [Abstract][Full Text] [Related]
15. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator. Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898 [TBL] [Abstract][Full Text] [Related]
16. Advances in the management of acute ischemic stroke. Nair R; Wagner AN; Buck BH Curr Opin Neurol; 2023 Apr; 36(2):147-154. PubMed ID: 36762632 [TBL] [Abstract][Full Text] [Related]
17. Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI. Guo C; Bai Q; Zhao Z; Zhang J Cerebrovasc Dis; 2019; 48(1-2):85-90. PubMed ID: 31587000 [TBL] [Abstract][Full Text] [Related]
18. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design. Albers GW; Campbell BC; Lansberg MG; Broderick J; Butcher K; Froehler MT; Schwamm LH; Nouh AM; Liebeskind DS; Toy F; Yang M; Massaro L; Schoeffler M; Purdon B Int J Stroke; 2023 Feb; 18(2):237-241. PubMed ID: 35262424 [TBL] [Abstract][Full Text] [Related]